Compare Expensify Inc (EXFY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Organon & Co. Common Stock — how do they compare? Expensify Inc trades at $2.48 (market cap $223.41M), while Organon & Co. Common Stock trades at $13.77 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 16.2× Expensify Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Organon & Co. Common Stock for 0 Days on average.
| EXFY | OGN | |
|---|---|---|
Market Cap | $223.41M | $3.61B |
Volume | 450,483 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $2.72 | $13.81 |
52-Week Low | $0.75 | $5.70 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $163.03M | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.44, showing stability with no recent price change. The stock exhibits a bullish technical signal from moving averages, while oscillators are neutral. Fundamentally, the company reported revenue of $142.10 million in 2025 but a net loss of $21.39 million, with negative profit margins and high P/E ratio of 258.82 indicating premium valuation despite losses. Recent positive developments include new AI integrations and European card expansion, alongside improved cash flow trends.
The outlook is mixed; analyst consensus is bullish with a $13.75 price target, but persistent net losses and competitive pressures pose risks. Investment opportunity hinges on successful execution of AI-driven growth and profitability improvements, while key risks include sustained unprofitability and market volatility.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
